Adenovirus-based RSV Vaccine Shows No Enhanced Disease
Author Information
Author(s): Anja Krause, Yaqin Xu, Sara Ross, Wendy Wu, Ju Joh, Stefan Worgall
Primary Institution: Weill Medical College of Cornell University
Hypothesis
Does immunization with an RGD-modified adenovirus vector induce a protective immune response against RSV without causing vaccine-enhanced disease?
Conclusion
The study found that the adenovirus-based vaccine did not trigger vaccine-enhanced RSV disease and induced a strong protective immune response.
Supporting Evidence
- Immunization with AdF.RGD resulted in increased RSV-specific IFN-γ T cell responses.
- AdF.RGD did not induce pulmonary inflammatory responses seen with FIRSV.
- The study demonstrated that AdF.RGD provides protective immunity against RSV without enhancing disease.
Takeaway
Researchers created a new vaccine for a virus that makes kids sick, and it worked well without causing extra problems.
Methodology
BALB/c mice were immunized with either the adenovirus vector or formalin-inactivated RSV and then challenged with RSV to evaluate immune responses and disease enhancement.
Participant Demographics
Female BALB/c mice, 6 to 8 weeks old.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website